Pyridam Farma Tbk (PYFA) - Total Assets
Based on the latest financial reports, Pyridam Farma Tbk (PYFA) holds total assets worth Rp6.92 Trillion IDR (≈ $405.45 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pyridam Farma Tbk - Total Assets Trend (2001–2024)
This chart illustrates how Pyridam Farma Tbk's total assets have evolved over time, based on quarterly financial data. Also see PYFA stock market capitalisation for the company's overall valuation and market capitalisation.
Pyridam Farma Tbk - Asset Composition Analysis
Current Asset Composition (December 2024)
Pyridam Farma Tbk's total assets of Rp6.92 Trillion consist of 26.5% current assets and 73.6% non-current assets. Review total liabilities of Pyridam Farma Tbk to assess the company's total debt and financial obligations.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 6.1% |
| Accounts Receivable | Rp652.96 Billion | 11.2% |
| Inventory | Rp457.17 Billion | 7.9% |
| Property, Plant & Equipment | Rp1.53 Trillion | 26.3% |
| Intangible Assets | Rp881.75 Billion | 15.2% |
| Goodwill | Rp1.71 Trillion | 29.4% |
Asset Composition Trend (2001–2024)
This chart illustrates how Pyridam Farma Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Pyridam Farma Tbk (PYFA) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pyridam Farma Tbk's current assets represent 26.5% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2024, up from 1.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 29.4% of total assets.
Pyridam Farma Tbk Competitors by Total Assets
Key competitors of Pyridam Farma Tbk based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Pyridam Farma Tbk - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 0.74 | 2.89 |
| Quick Ratio | 0.74 | 0.52 | 1.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp85.76 Billion | Rp-607.04 Billion | Rp84.59 Billion |
Pyridam Farma Tbk - Advanced Valuation Insights
This section examines the relationship between Pyridam Farma Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.97 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 282.0% |
| Total Assets | Rp5.81 Trillion |
| Market Capitalization | $169.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pyridam Farma Tbk's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pyridam Farma Tbk's assets grew by 282.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pyridam Farma Tbk (2001–2024)
The table below shows the annual total assets of Pyridam Farma Tbk from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp5.81 Trillion ≈ $340.51 Million |
+282.00% |
| 2023-12-31 | Rp1.52 Trillion ≈ $89.14 Million |
+0.04% |
| 2022-12-31 | Rp1.52 Trillion ≈ $89.10 Million |
+88.60% |
| 2021-12-31 | Rp806.22 Billion ≈ $47.24 Million |
+252.72% |
| 2020-12-31 | Rp228.58 Billion ≈ $13.39 Million |
+19.81% |
| 2019-12-31 | Rp190.79 Billion ≈ $11.18 Million |
+1.99% |
| 2018-12-31 | Rp187.06 Billion ≈ $10.96 Million |
+17.23% |
| 2017-12-31 | Rp159.56 Billion ≈ $9.35 Million |
-4.49% |
| 2016-12-31 | Rp167.06 Billion ≈ $9.79 Million |
+4.45% |
| 2015-12-31 | Rp159.95 Billion ≈ $9.37 Million |
-7.31% |
| 2014-12-31 | Rp172.56 Billion ≈ $10.11 Million |
-1.46% |
| 2013-12-31 | Rp175.12 Billion ≈ $10.26 Million |
+28.91% |
| 2012-12-31 | Rp135.85 Billion ≈ $7.96 Million |
+15.09% |
| 2011-12-31 | Rp118.03 Billion ≈ $6.92 Million |
+17.34% |
| 2010-12-31 | Rp100.59 Billion ≈ $5.89 Million |
+0.65% |
| 2009-12-31 | Rp99.94 Billion ≈ $5.86 Million |
+1.30% |
| 2008-12-31 | Rp98.66 Billion ≈ $5.78 Million |
+3.68% |
| 2007-12-31 | Rp95.16 Billion ≈ $5.58 Million |
+14.47% |
| 2006-12-31 | Rp83.13 Billion ≈ $4.87 Million |
+8.59% |
| 2005-12-31 | Rp76.55 Billion ≈ $4.49 Million |
+8.69% |
| 2004-12-31 | Rp70.43 Billion ≈ $4.13 Million |
+3.17% |
| 2003-12-31 | Rp68.27 Billion ≈ $4.00 Million |
-2.13% |
| 2002-12-31 | Rp69.75 Billion ≈ $4.09 Million |
-9.02% |
| 2001-12-31 | Rp76.67 Billion ≈ $4.49 Million |
-- |
About Pyridam Farma Tbk
PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates through Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extra… Read more